Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C.
Matsuura K, Watanabe T, Iijima S, Murakami S, Fujiwara K, Orito E, Iio E, Endo M, Kusakabe A, Shinkai N, Miyaki T, Nojiri S, Joh T, Tanaka Y. Matsuura K, et al. Among authors: fujiwara k. Hepatol Res. 2014 Nov;44(12):1208-1216. doi: 10.1111/hepr.12294. Epub 2014 Feb 17. Hepatol Res. 2014. PMID: 24372894
Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
Iio E, Shimada N, Takaguchi K, Senoh T, Eguchi Y, Atsukawa M, Tsubota A, Abe H, Kato K, Kusakabe A, Miyaki T, Matsuura K, Matsunami K, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Iio E, et al. Among authors: fujiwara k. Hepatol Res. 2017 Nov;47(12):1308-1316. doi: 10.1111/hepr.12898. Epub 2017 May 6. Hepatol Res. 2017. PMID: 28332272
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.
Suzuki T, Matsuura K, Urakabe K, Okumura F, Kawamura H, Sobue S, Matoya S, Miyaki T, Kimura Y, Kato D, Kusakabe A, Tanaka Y, Ozasa A, Nagura Y, Fujiwara K, Nojiri S, Hagiwara S, Kusumoto S, Inoue T, Tanaka Y, Kataoka H. Suzuki T, et al. Among authors: fujiwara k. Hepatol Res. 2023 Apr;53(4):289-300. doi: 10.1111/hepr.13864. Epub 2022 Dec 16. Hepatol Res. 2023. PMID: 36461885
The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
Matoya S, Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kuroyanagi K, Kusakabe A, Koguchi H, Hasegawa I, Miyaki T, Tanaka Y, Kondo H, Kimura Y, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group (SLSG). Matoya S, et al. Among authors: fujiwara k. Hepatol Res. 2023 Jun;53(6):511-521. doi: 10.1111/hepr.13886. Epub 2023 Feb 18. Hepatol Res. 2023. PMID: 36723964
Serum inducible protein 10 kDa/C-X-C motif chemokine 10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
Nagura Y, Suzuki T, Matsuura K, Ogawa S, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Nagaoka K, Iio E, Watanabe T, Kataoka H, Tanaka Y. Nagura Y, et al. Among authors: fujiwara k. Hepatol Res. 2024 Jan;54(1):32-42. doi: 10.1111/hepr.13962. Epub 2023 Sep 6. Hepatol Res. 2024. PMID: 37638483
A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.
Orito E, Fujiwara K, Tanaka Y, Yuen MF, Lai CL, Kato T, Sugauchi F, Kusakabe A, Sata M, Okanoue T, Niitsuma H, Sakugawa H, Hasegawa I, Mizokami M. Orito E, et al. Among authors: fujiwara k. Hepatol Res. 2006 Jun;35(2):127-34. doi: 10.1016/j.hepres.2006.03.005. Epub 2006 Apr 19. Hepatol Res. 2006. PMID: 16621686
3,521 results